dolutegravir; lamivudine; tenofovir disoproxil fumarate
DOLUTEGRAVIR, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE (dolutegravir; lamivudine; tenofovir disoproxil fumarate) by Shanghai Sunway Biotech is fixed-dose combination of the hiv‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see microbiology ()]. Approved for hiv-1 infection in adults, weighing at least 6 kg.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
A fixed-dose combination tablet containing dolutegravir (integrase strand transfer inhibitor), lamivudine (nucleoside reverse transcriptase inhibitor), and tenofovir disoproxil fumarate (nucleotide reverse transcriptase inhibitor) for treatment of HIV-1 infection. This triple-agent oral formulation simplifies antiretroviral therapy by combining three complementary mechanisms to suppress viral replication. Indicated for adults and pediatric patients weighing at least 6 kg with HIV-1 infection.
Early-stage asset with undefined commercial trajectory; team build and market access strategy will be critical to competitive positioning in crowded HIV FDC space.
fixed-dose combination of the HIV‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see Microbiology ()].
Worked on DOLUTEGRAVIR, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE at Shanghai Sunway Biotech? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
This pre-launch asset offers entry-level to mid-career professionals the opportunity to build a brand from ground zero in a high-volume therapeutic area with established demand. Career growth will be accelerated if the product achieves rapid regulatory approval and geographic expansion, but constrained by generic competition and limited patent runway.